Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.29%
-1.32%
-14.99%
+22.09%
-1.56%
APGE
Apogee Therapeutics Inc.
$53.21
Login to see Apogee Therapeutics Inc. (APGE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Outperform the market
Chart
$37.27 (+42.77%)
$37.79 (+40.80%)
$37.79 (+40.80%)
$37.79 (+40.80%)
APGE has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
APGE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Outperform the market
APGE Analysts opinion is positive and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
APGE Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayAPGE Earnings
The TTM reflects 12-month period, providing review of APGE financial performance.
The company financial health has deteriorated over the past year
Financial Score
What is APGE current stock price?
What are APGE stock strengths?
What risks are associated with APGE stock?
When is APGE next earnings report?
What is APGE market cap and volume?
What is APGE's current Stock IQ?
Should I buy APGE stock right now?
Is APGE a Strong Buy right now?
What does a 'Strong Buy' rating mean for APGE?
What does a 'Strong Sell' rating mean for APGE?
What factors influence APGE's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.29%
-1.32%
-14.99%
+22.09%
-1.56%
APGE
Apogee Therapeutics Inc.
Current Price
$53.21
Stock Insights
Strengths
Upgraded on attractively valued
Outperform the market
Login to unlock Apogee Therapeutics Inc. (APGE) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$37.27 (+42.77%)
$37.79 (+40.80%)
$37.79 (+40.80%)
$37.79 (+40.80%)
APGE Analysts Opinion
APGE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Outperform the market
APGE Analysts opinion is positive and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
APGE Street view is extremely bullish and have positive views on the near-term outlook
APGE has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayAPGE Earnings
The TTM data reflects the most recent 12-month period, providing overview of APGE financial performance.
APGE Financial Health
The company financial health has deteriorated over the past year
Financial Score
APGE Latest Analysis
Apogee Therapeutics prices $300M public offering.
Today
Apogee Therapeutics announces underwritten public offering.
Wed Oct 8, 2025
Apogee Therapeutics stock falls after announcing proposed public offering.
Wed Oct 8, 2025
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating. Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best strong buy stocks to invest in according to Wall Street. On September 25 RBC Capital initiated coverage of Apogee Therapeutics Inc. (NASDAQ:APGE) with an Outperform rating and a $60 price target. The firm expressed optimistic sentiments regarding the companys potential to deliver clinically differentiated biologics telling [….]
Tue Sep 30, 2025
Apogee Therapeutics (APGE) Shares Cross Above 200 DMA. In trading on Monday shares of Apogee Therapeutics Inc (Symbol: APGE) crossed above their 200 day moving average of $38.95 changing hands as high as $39.45 per share. Apogee Therapeutics Inc shares are currently trading up about 2.5% on the day. The chart below shows the one
Mon Sep 29, 2025
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation. Fintel reports that on September 25 2025 RBC Capital initiated coverage of Apogee Therapeutics (NasdaqGM:APGE) with a Outperform recommendation. Analyst Price Forecast Suggests 159.85% Upside
Thu Sep 25, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
APGE Stock trends
APGE Stock performance
APGE Stock analysis
APGE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings
Leaders